IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

(marketscreener.com) Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025Initiated IDE397 Phase 2 monotherapy expansion cohorts and Phase 1 combination dose escalation cohorts in solid tumors with MTAP deletionEntered into Clinical Trial Collaboration and Supply...https://www.marketscreener.com/quote/stock/IDEAYA-BIOSCIENCES-INC-58457878/news/IDEAYA-Biosciences-Inc-Reports-Second-Quarter-2022-Financial-Results-and-Provides-Business-Update-41315217/?utm_medium=RSS&utm_content=20220815